Book a Meeting

Non-Fucosylated Anti-Human CEA (PR1A3) Therapeutic Antibody (CAT#: BioBet-1691ZP) Datasheet

Target
CEA
Isotype
IgG
Description
Non-Fucosylated Anti-Human CEA (PR1A3) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CEA antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CEA
Alternative Names
altumomab pentetate;hybri-ceaker;156586-92-4;ZCE 025;Hybri-ceaker;USP;indium In 111 altumomab pentetate;CEACAM1;carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein);BGP;BGP1;BGPI;antigen CD66;CD66a antigen;CEACAM3;carcinoembryo
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
PR1A3
Host
Humanized
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany